ChemotherapyFDA-approvedSecond-line
Cabazitaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, cabazitaxel significantly improved overall survival and delayed disease progression in patients with metastatic castration-resistant prostate cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Cabazitaxel vs Lu-PSMA in Prostate Cancer: Cost and Effectiveness Compared | Prostate Cancer | phase-3 | Lu-PSMA demonstrated improved PSA response (66% vs 37%) and progression-free survival (HR = 0.63). | Source → |
| Combining Two Drugs May Improve Treatment for Aggressive Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Taxane Allergy: Unexpected Reaction to Cabazitaxel | Prostate Cancer | observational | — | Source → |
| Cabazitaxel Dosage May Affect Prostate Cancer Treatment Outcomes | Prostate Cancer | phase-3 | The OS effect of C25 increased with risk quartiles: -0.07 months (95% CI, -1.60 to 1.46) in the lowest risk quartile and 1.67 months (95% CI, 0.25 to 3.10) in the highest risk quartile. | Source → |
| Severe Neutropenia Risk in Prostate Cancer Patients on Cabazitaxel | Prostate Cancer | observational | — | Source → |
| New Nanoparticle Delivery System for Prostate Cancer Treatment | Prostate Cancer | animal-study | The high-dose CTX-NP group showed a tumor inhibition rate of 79.48%. | Source → |
| New Strategy to Combat Ovarian Cancer Resistance Identified | Ovarian Cancer | lab-study | — | Source → |
| Cabazitaxel Side Effect: Ureteritis in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Cabazitaxel Efficacy in Very Elderly Prostate Cancer Patients | Prostate Cancer | observational | There was no significant difference in therapeutic efficacy between patients under 80 and those 80 or older. | Source → |
| Lu-PSMA Therapy Compared to Cabazitaxel in Advanced Prostate Cancer | Prostate Cancer | observational | Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for Lu-PSMA versus cabazitaxel. | Source → |
| Lu-177 PSMA Treatment Compared in Prostate Cancer Study | Prostate Cancer | phase-3 | The Lu-177 PSMA treatment groups in TheraP and VISION had similar OS (HR, 0.92 [95% CI, 0.70-1.19]). | Source → |
| Enhancing Cancer Treatment with Fatty Acids | Prostate Cancer | lab-study | Dextran-GLA-CTX exhibited the strongest antitumor activity. | Source → |
| Link Found Between Resistance to Two Prostate Cancer Drugs | Prostate Cancer | lab-study | — | Source → |
| Cabazitaxel Efficacy in Prostate Cancer Patients | Prostate Cancer | phase-3 | PSA-RR ≥ -50% was 26% (12/48) and BSI-change rate ≥ -50% was 17% (8/41). | Source → |
| Docetaxel Response Affects Cabazitaxel Sensitivity in Prostate Cancer | Prostate Cancer | observational | None of the patients with a poor response to prior docetaxel therapy responded well to cabazitaxel therapy. | Source → |
| Lab Study on Prostate Cancer Cells' Resistance to Treatment | Prostate Cancer | lab-study | — | Source → |
| Genetic Variants May Affect Prostate Cancer Treatment | Prostate Cancer | lab-study | The hazard ratio for -rs151352 was 0.52, and -rs1341164 was 0.53, indicating better overall survival. | Source → |
| Long-term use of cabazitaxel for prostate cancer treatment | Prostate Cancer | observational | — | Source → |
| Cabazitaxel treatment may help fight prostate cancer by boosting immune response | Prostate Cancer | lab-study | — | Source → |
| New Potential Treatment for Prostate Cancer Resistant to Cabazitaxel | Prostate Cancer | lab-study | — | Source → |
| New Delivery System for Melanoma Treatment | Melanoma | lab-study | — | Source → |
| Cabazitaxel Prodrug Nanoparticles Show Promise in Cancer Therapy | Melanoma | lab-study | — | Source → |
| Cabazitaxel's Effect on Prostate Cancer Cells | Prostate Cancer | lab-study | CAB exerted considerably cytotoxic and apoptotic effects on PC-3 mCRPC cells (p < 0.05). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.